Cronos Group Inc. ($CRON) Stock Forecast: Up 5.1% Today

What is Cronos Group Inc.?

Cronos Group Inc. (NASDAQ: CRON) operates in the global cannabis sector, navigating challenges like negative net margin and return on equity while pursuing international expansion.

Why is Cronos Group Inc. going up?

CRON stock is up 5.1% on Apr 15, 2026 18:01

• Cronos Group's stock (CRON) surged by 1.18% to $2.58, marking a three-day uptrend.
• Analysts have revised Cronos Group's price target to CA$4.50, highlighting the company's strong Canadian brands, focus on efficient revenue growth, and quality cultivation practices as growth catalysts.
• The company's market sentiment has improved due to its entry into the Swiss market and the launch of new products under well-established brands like Spinach and Lord Jones.
• Despite ongoing profitability challenges, Cronos Group's strategic advancements and positive analyst outlook have driven its stock performance above market trends.

CRON Price Chart

CRON Technical Analysis

CRON News

Cronos Group Inc. (NASDAQ:CRON) Receives Consensus Recommendation of "Hold" from Analysts

Analysts have given Cronos Group Inc. (NASDAQ:CRON) a consensus "Hold" rating, with an average 12-month price target of $2.30. Despite recently beating EPS and revenue estimates, the company shows a negative net margin of -6.44%. Institutional investors and hedge funds have recently adjusted their holdings in CRON, which currently trades around $2.57.

https://www.marketbeat.com/instant-alerts/cronos-group-inc-nasdaqcron-receives-consensus-recommendation-of-hold-from-analysts-2026-04-15/

Cronos grows international footprint in Switzerland

This article from MSN announces that Cronos has expanded its international presence by entering the Swiss market. Further details about the expansion (e.g., specific products, partnerships, or scale) are not provided in the given input.

https://www.msn.com/en-us/money/smallbusiness/cronos-grows-international-footprint-in-switzerland/ar-AA1HPIOv?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Cronos Group (NASDAQ:CRON) Trading Down 0.4% - Here's What Happened

Cronos Group (NASDAQ:CRON) saw its shares dip by 0.4% to $2.57 on Monday, with trading volume slightly below its daily average. The company faces a mixed analyst outlook, holding an average "Hold" rating and a target price of $2.30, despite beating quarterly earnings and revenue expectations. Although Cronos Group remains unprofitable with a negative net margin and return on equity, institutional investors have adjusted their holdings, and the company continues to operate in the cannabis market with various branded products.

https://www.marketbeat.com/instant-alerts/cronos-group-nasdaqcron-trading-down-04-heres-what-happened-2026-04-14/

Cronos Group Inc. stock rises Friday, outperforms market

Shares of Cronos Group Inc. (CRON) rose 1.18% on Friday, closing at $2.58. This gain occurred during a mixed trading session where the NASDAQ Composite Index increased by 0.35%, and the Dow Jones Industrial Average fell by 0.56%. The stock experienced its third consecutive day of gains.

https://www.marketwatch.com/data-news/cronos-group-inc-stock-rises-friday-outperforms-market-5393ac94-b725f8c8cc2a

CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside

Analysts have reset Cronos Group's price target to CA$4.50, acknowledging the company's established Canadian brands, a focus on scaling revenue with a lean cost base, and quality cultivation practices. While bullish sentiments highlight the potential for revenue growth and profitability driven by brand strength and cost management, bearish views question the pace of top-line growth and margin preservation in a competitive market. Recent company news includes share repurchases, new product launches under the Spinach brand, and expansion of the Lord Jones brand into the Israeli medical cannabis market.

https://simplywall.st/community/narratives/ca/pharmaceuticals-biotech/tsx-cron/cronos-group-shares/wv2w6xp6-growco-capacity-and-global-markets-will-unlock-potential-u68u/updates/5-analysts-have-reset-their-price-target-for-cronos-group-to-c

Trending Today

Gasoline ($GASOLINE) Commodity Forecast: Down 5.2% Today

Dow Inc. ($DOW) Stock Forecast: Down 10.2% Today

Netflix Inc. ($NFLX) Stock Forecast: Down 9.8% Today

Harley-Davidson Inc. ($HOG) Stock Forecast: Up 5.0% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 9.7% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 11.4% Today

SiteOne Landscape Supply Inc. ($SITE) Stock Forecast: Up 5.5% Today

Blink Charging Co. ($BLNK) Stock Forecast: Up 6.8% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 6.7% Today

Xerox Corporation ($XRX) Stock Forecast: Up 11.6% Today

Cronos Group Inc. Price History

29.00.2026 - CRON Stock was down 7.0%

• Analysts at Canaccord Genuity Group issued a "buy" rating with a target price of C$4.25, indicating a possible upside. The general analyst consensus, however, continues to suggest a "Hold," with the average price target at $2.30.
• Although the company boasts a solid financial position with no debts and substantial cash reserves amounting to $824 million, concerns over a negative EPS forecast for the current fiscal year might have influenced the recent market decline.
• The company's strong operational performance and revenue growth in Q3 2025, largely propelled by the success of the Spinach brand and expansion initiatives, were somewhat overshadowed by uncertainties surrounding future profitability.
• The discussion of alternative AI stocks offering greater potential for market growth could have diverted investor focus from Cronos Group, contributing to its recent stock performance downturn.

19.11.2025 - CRON Stock was down 6.8%

• The bearish movement in CRON today could be attributed to profit-taking by investors after a series of significant stock price surges in response to the company's European expansion efforts.
• Despite the positive news of Cronos Group's strategic acquisition of CanAdelaar and its expansion into Europe, investors may be reevaluating the stock's valuation, which has been considered overvalued by some analysts.
• The high valuation and potential risks associated with delays or policy reversals in the cannabis sector may have contributed to the bearish sentiment towards CRON today.
• While the company's moves to capitalize on the evolving cannabis markets are promising, investors may be exercising caution amidst concerns about sustainability and profitability in the long term.

15.11.2025 - CRON Stock was down 5.0%

• Despite recent positive developments in Cronos Group's expansion into Europe and the surge in its stock price, today's bearish movement could be attributed to profit-taking by investors after a period of strong gains.
• Concerns about overvaluation and potential risks such as policy reversals or revenue growth delays might have contributed to the downward pressure on CRON's stock.
• Investors may be reevaluating their positions in CRON, considering the mixed financial metrics and the company's premium valuation compared to industry peers.
• While Cronos Group's strategic acquisitions and market expansions have generated positive feedback, market participants are likely being cautious amidst uncertainties in the cannabis sector and broader market conditions.

09.11.2025 - CRON Stock was up 6.4%

• The bullish movement in CRON stock today could be attributed to the strategic partnership announced between Crypto.com and 21shares to expand access to the Cronos ecosystem. This partnership is likely seen as a positive development for Cronos Group, potentially boosting investor confidence in the company's future prospects.
• Despite the slight dip in CRON shares recently, the overall market sentiment seems to have been positively influenced by the news of the strategic partnership. Investors may be focusing more on the long-term growth potential of Cronos Group rather than short-term fluctuations in share price.
• The announcement of new investment products tracking the Cronos token could have also contributed to the bullish movement, as it indicates increasing interest and adoption of Cronos' ecosystem, potentially driving up demand for the company's products and services.

22.11.2025 - CRON Stock was down 5.1%

• The stock fell on Wednesday, underperforming the overall market, which could be attributed to profit-taking or market correction.
• Despite being considered a safer bet in the cannabis industry due to its strong financial position and disciplined management, the high valuation and limited direct benefits from potential US cannabis rescheduling might have dampened investor enthusiasm.
• The company's improved gross margins and profitability could be overshadowed by the broader market sentiment or sector-specific challenges, leading to the bearish movement in the stock today.
• Investors may be reevaluating their positions in CRON amidst uncertainties surrounding cannabis regulations and market dynamics, contributing to the downward pressure on the stock price.

12.00.2026 - CRON Stock was up 2.6%

• Cronos' bullish movement was driven by its recent announcement of expanding into the Netherlands through the acquisition of Europe’s largest adult-use cannabis company. This strategic move is expected to unlock new revenue streams and enhance Cronos' position in the global cannabis market.
• Furthermore, positive trading plans and investment analysis on CRON:CA may have also influenced the stock's upward momentum. Analysts and AI-generated ratings suggesting buying at specific price levels and implementing stop-loss measures could have instilled confidence in investors.
• In conclusion, Cronos' strategic expansion initiatives, along with favorable trading recommendations and investment analysis, have instilled optimism among investors, triggering the significant bullish movement observed in the stock today.

03.01.2026 - CRON Stock was up 5.1%

• The bullish movement in CRON today can be attributed to the launch of its premium cannabis brand, Lord Jones®, in Israel. This strategic expansion into new markets with high-quality products showcases the company's commitment to growth and innovation.
• Additionally, the bullish thesis surrounding potential regulatory changes in the US, specifically the reclassification of marijuana as a Schedule III substance, has likely fueled investor optimism. This shift could lead to improved financial performance for CRON by reducing tax burdens and enhancing operational efficiency.
• Despite recent declines and cautious Wall Street analyst ratings, CRON's forward-thinking approach to product strategy and potential regulatory tailwinds seem to have resonated positively with investors, driving the stock's bullish momentum today.

29.08.2025 - CRON Stock was up 2.3%

• President Trump's support for CBD on Truth Social led to a surge in cannabis stock prices, including CRON.
• Despite the initial increase, CRON experienced a drop in market cap erasing the gains following Trump's post.
• There are concerns in the community regarding the demand for CRON after the market rally, indicating a possible shift in sentiment.
• The fluctuating movements in CRON following Trump's post highlight the unpredictable nature of cannabis stocks in response to political and regulatory developments.

25.02.2026 - CRON Stock was up 5.2%

• Cronos Group Inc. (CRON) has been experiencing consecutive days of stock price increases, outperforming the broader market.
• Positive news such as beating EPS and revenue expectations in recent earnings reports and legislative efforts to protect legal cannabis businesses in the U.S. have likely contributed to the bullish momentum.
• Insider trading activity, with an officer exercising restricted stock units and increasing their direct holdings, may also signal confidence in the company's future prospects.
• The overall positive sentiment towards the cannabis sector and specific company developments seem to be driving the bullish movement in CRON stock despite its unprofitable status and negative margins.

15.03.2026 - CRON Stock was up 5.1%

• Cronos Group's stock (CRON) surged by 1.18% to $2.58, marking a three-day uptrend.
• Analysts have revised Cronos Group's price target to CA$4.50, highlighting the company's strong Canadian brands, focus on efficient revenue growth, and quality cultivation practices as growth catalysts.
• The company's market sentiment has improved due to its entry into the Swiss market and the launch of new products under well-established brands like Spinach and Lord Jones.
• Despite ongoing profitability challenges, Cronos Group's strategic advancements and positive analyst outlook have driven its stock performance above market trends.

12.11.2025 - CRON Stock was up 8.2%

• CRON stock surged by 7.56% after acquiring CanAdelaar, Europe's largest adult-use cannabis company. This acquisition provides Cronos Group with a strong presence in the growing European market, leading to increased investor optimism.
• The company's strategic move into Europe's medical cannabis market and the acquisition of CanAdelaar are viewed as positive growth opportunities, driving up the stock price.
• Investors are analyzing the potential impact of this expansion on Cronos Group's market share and premium products, which have contributed to the bullish market movement.
• Despite regulatory risks in Europe, Cronos Group's CEO highlighted the financial and strategic significance of the expansion, boosting investor confidence in the company's future prospects.

10.11.2025 - CRON Stock was up 6.3%

• The positive market sentiment surrounding CRON stock is linked to its acquisition of CanAdelaar B.V., which expands Cronos Group's reach in the European adult-use cannabis market.
• Entering the European market is viewed as a strategic move to enhance Cronos's product development capabilities and global cannabinoid presence, attracting investor interest.
• The partnership with Crypto.com and 21shares is enhancing access to the Cronos ecosystem and creating new investment opportunities, contributing to the bullish momentum.
• Despite challenges like negative net margins and return on equity, Cronos Group's expansion efforts and strategic acquisitions have boosted investor confidence, reflected in the upward movement of its stock price.